AQW-051

Research use only, not for human use.

AQW-051 is a novel, potent and selective, orally bioavailable, brain-penetrant α7 nAChR partial agonist with pKd of 7.56.

AQW-051 is a novel, potent and selective, orally bioavailable, brain-penetrant α7 nAChR partial agonist with pKd of 7.56; displays high selectivity (>100-fold) over other nACh receptors; stimulates calcium influx in GH3–ha7-22 cells recombinantly expressing the human α7-nACh receptor with pEC50 of 7.41; facilitates learning/memory performance in mice; reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.Parkinson Disease Phase 2 Clinical.

——

Animal Model:OF1/IC strain adult miceDosage:0.03 and 0.3 mg/kg Administration:Oral administration; 0.03 and 0.3 mg/kg once Result:Increased the learning/memory performance with more time to scrutinize the novel partner than the familiar partner during the re-test trial at 24 h. Showed cognitive-enhancing effects in mice by the object recognition test (ORT).

AQW051 | AQW 051

Membrane Transporter/Ion Channel

nAChR

nAChR

Neurological Disease

Parkinson Disease

669770-29-0

294.398

C19H22N2O

>98% (HPLC)

In Vitro:?DMSO : 16.67 mg/mL (56.63 mM)

CC1=CC=C(C2=CC=C(O[C@H]3CN4CCC3CC4)C=N2)C=C1

(3R)-3-{[6-(4-methylphenyl)pyridin-3-yl]oxy}-1-azabicyclo[2.2.2]octane

(-20℃)

With Ice Pack

≥ 2 years